Johannes Peter Stasch

Summary

Affiliation: Bayer HealthCare
Country: USA

Publications

  1. doi request reprint Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence
    Johannes Peter Stasch
    Bayer Pharma AG, Wuppertal, Germany University Halle Wittenberg, Germany Electronic address
    Curr Opin Pharmacol 21:95-104. 2015
  2. doi request reprint Soluble guanylate cyclase stimulators in pulmonary hypertension
    Johannes Peter Stasch
    Cardiology Research, Bayer Pharma AG, Aprather Weg 18a, 42096, Wuppertal, Germany
    Handb Exp Pharmacol 218:279-313. 2013
  3. ncbi request reprint Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase
    Peter M Schmidt
    Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany
    Eur J Pharmacol 513:67-74. 2005
  4. pmc Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer AG, Pharma Research Center, Wuppertal, Germany
    Br J Pharmacol 135:333-43. 2002
  5. ncbi request reprint Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase
    Peter Schmidt
    Institute of Cardiovascular Research, Bayer AG, Aprather Weg 18a, D 42096, Wuppertal, Germany
    Eur J Pharmacol 468:167-74. 2003
  6. pmc Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells
    Linda S Hoffmann
    Pharma Research Centre, Bayer HealthCare, Wuppertal, Germany
    PLoS ONE 6:e23596. 2011
  7. pmc Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany
    J Clin Invest 116:2552-61. 2006
  8. pmc Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer AG, Pharma Research Center, Wuppertal, Germany
    Br J Pharmacol 135:344-55. 2002
  9. ncbi request reprint Identification of residues crucially involved in soluble guanylate cyclase activation
    Christiane Rothkegel
    Cardiovascular Research, Bayer HealthCare, Aprather Weg 18a, D 42096 Wuppertal, Germany
    FEBS Lett 580:4205-13. 2006
  10. doi request reprint The chemistry and biology of soluble guanylate cyclase stimulators and activators
    Markus Follmann
    Bayer Pharma Aktiengesellschaft, Global Drug Discovery, Aprather Weg 18a, 42113 Wuppertal, Germany
    Angew Chem Int Ed Engl 52:9442-62. 2013

Collaborators

Detail Information

Publications24

  1. doi request reprint Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence
    Johannes Peter Stasch
    Bayer Pharma AG, Wuppertal, Germany University Halle Wittenberg, Germany Electronic address
    Curr Opin Pharmacol 21:95-104. 2015
    ..Clinical trials are required to confirm these findings in humans, and to ascertain whether these agents could provide a future alternative to guideline-recommended treatments. ..
  2. doi request reprint Soluble guanylate cyclase stimulators in pulmonary hypertension
    Johannes Peter Stasch
    Cardiology Research, Bayer Pharma AG, Aprather Weg 18a, 42096, Wuppertal, Germany
    Handb Exp Pharmacol 218:279-313. 2013
    ..Finally, sGC stimulators may also have potential therapeutic applications in other diseases, including heart failure, lung fibrosis, scleroderma and sickle cell disease. ..
  3. ncbi request reprint Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase
    Peter M Schmidt
    Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany
    Eur J Pharmacol 513:67-74. 2005
    ..In this work, we show that replacement of the serine(137) with alanine destabilizes the binding of the heme moiety and impairs NO-mediated soluble guanylate cyclase activation...
  4. pmc Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer AG, Pharma Research Center, Wuppertal, Germany
    Br J Pharmacol 135:333-43. 2002
    ..These results suggest that BAY 41-8543 is on the one hand an invaluable tool for studying sGC signaling in vitro and on the other hand its unique profile may offer a novel approach for treating cardiovascular diseases...
  5. ncbi request reprint Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase
    Peter Schmidt
    Institute of Cardiovascular Research, Bayer AG, Aprather Weg 18a, D 42096, Wuppertal, Germany
    Eur J Pharmacol 468:167-74. 2003
    ..These results show the different activation patterns of both compounds and demonstrate their value as tools to investigate the mechanisms that underlie soluble guanylyl cyclase activation...
  6. pmc Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells
    Linda S Hoffmann
    Pharma Research Centre, Bayer HealthCare, Wuppertal, Germany
    PLoS ONE 6:e23596. 2011
    ..Nevertheless, it allows to monitor sGC's redox regulation in living cells and future enhancements might be able to extend this approach to in vivo conditions...
  7. pmc Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany
    J Clin Invest 116:2552-61. 2006
    ....
  8. pmc Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies
    Johannes Peter Stasch
    Institute of Cardiovascular Research, Bayer AG, Pharma Research Center, Wuppertal, Germany
    Br J Pharmacol 135:344-55. 2002
    ....
  9. ncbi request reprint Identification of residues crucially involved in soluble guanylate cyclase activation
    Christiane Rothkegel
    Cardiovascular Research, Bayer HealthCare, Aprather Weg 18a, D 42096 Wuppertal, Germany
    FEBS Lett 580:4205-13. 2006
    ..In summary, the present work further elucidated intramolecular mechanisms underlying the NO- and BAY 41-2272-mediated sGC activation and raises questions regarding the postulated role of Tyr(145) for ligand discrimination...
  10. doi request reprint The chemistry and biology of soluble guanylate cyclase stimulators and activators
    Markus Follmann
    Bayer Pharma Aktiengesellschaft, Global Drug Discovery, Aprather Weg 18a, 42113 Wuppertal, Germany
    Angew Chem Int Ed Engl 52:9442-62. 2013
    ..The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clinical trials for different forms of pulmonary hypertension...
  11. ncbi request reprint Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase
    Peter Schmidt
    Institute of Cardiovascular Research, Bayer AG, 42096, Wuppertal, Germany
    Anal Biochem 314:162-5. 2003
  12. pmc Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats
    Sandra Geschka
    Cardiology Research, Bayer HealthCare, Wuppertal, Germany
    PLoS ONE 6:e21853. 2011
    ..Little is known about their effects on tissue remodeling and degeneration and survival in experimental malignant hypertension...
  13. doi request reprint Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis
    Andreas Knorr
    Institute of Cardiovascular Research, Bayer HealthCare AG, Wuppertal, Germany
    Arzneimittelforschung 58:71-80. 2008
    ..Stable cGMP analogues also reduce the contractile response of hepatic stellate cells. However, cGMP production is downregulated in the cirrhotic liver due to the reduced activity of the endothelial nitric oxide synthase...
  14. ncbi request reprint Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase
    Alexander Straub
    Institute of Medicinal Chemistry, Pharma Research Centre, Bayer AG, D 42096, Wuppertal, Germany
    Bioorg Med Chem 10:1711-7. 2002
    ..These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543...
  15. doi request reprint Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators
    Nils Griebenow
    Bayer Pharma AG, Global Drug Discovery, Medicinal Chemistry Wuppertal, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 23:1197-200. 2013
    ..Novel guanylate cyclase stimulators are disclosed. Design, synthesis, SAR, and pharmacological profile of the compounds are discussed...
  16. pmc Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
    Linda S Hoffmann
    Pharma Research Centre, Bayer HealthCare, Wuppertal, Germany
    PLoS ONE 10:e0145048. 2015
    ..These results underline the promising potential of cinaciguat to treat renal diseases by targeting the disease associated heme free form of sGC. ..
  17. ncbi request reprint Preparation of heme-free soluble guanylate cyclase
    Peter Schmidt
    Institute of Cardiovascular Research, Bayer AG, Aprather Weg 18a, D 42096, Wuppertal, Germany
    Protein Expr Purif 31:42-6. 2003
    ..In summary, the described procedure is suitable for the preparation of very small amounts of highly purified heme-free sGC for the investigation of the mechanism of action of different types of sGC activators...
  18. ncbi request reprint Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo
    Christiane Rothkegel
    Cardiovascular Research, Bayer HealthCare, Aprather Weg 18a, D 42096 Wuppertal, Germany
    Mol Pharmacol 72:1181-90. 2007
    ....
  19. ncbi request reprint Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, Aprather Weg 18a, 42096 Wuppertal, Germany
    ChemMedChem 1:96-105. 2006
    ..All ECE inhibitors of the indole class showed high selectivity for ECE over related metalloproteases such as NEP and ACE. Therefore, these compounds might have further potential as drugs for the treatment of coronary heart diseases...
  20. pmc Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension
    Eva Maria Becker
    Bayer Pharma AG, Cardiology Research, Wuppertal, Germany University Witten Herdecke, Fakultät für Gesundheit, Witten, Germany
    PLoS ONE 8:e73502. 2013
    ..Thus, so far these treatments have largely failed in secondary forms of PH...
  21. doi request reprint Structure/activity relationships of (M)ANT- and TNP-nucleotides for inhibition of rat soluble guanylyl cyclase α1β1
    Stefan Dove
    Department of Medicinal Chemistry II, University of Regensburg, Regensburg, Germany S D Institute of Pharmacology, K Y D, V K, R S and Research Core Unit Metabolomics V K, Hannover Medical School, Hannover, Germany and Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany J P S
    Mol Pharmacol 85:598-607. 2014
    ..Moreover, it may become possible to develop mAC inhibitors with selectivity relative to sGC. ..
  22. ncbi request reprint Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy
    Harald Lapp
    Herzzentrum Wuppertal, HELIOS Klinikum, Wuppertal, Germany
    Int J Cardiol 94:93-7. 2004
    ..Little is known about the pathophysiological relevance of hU-II. We hypothesised that circulating hU-II is elevated in patients with coronary artery disease (CAD) corresponding to the degree of cardiac dysfunction...
  23. ncbi request reprint 4-Phenyl-4H-pyrans as IK(Ca) channel blockers
    Klaus Urbahns
    Institute of Medicinal Chemistry, Pharma Research Center, Bayer AG, D 42096, Wuppertal, Germany
    Bioorg Med Chem Lett 13:2637-9. 2003
    ..Their synthesis and structure-activity relationships are described. A selected derivative, rac-11, reduces the infarct volume in a rat subdural hematoma model of traumatic brain injury after iv administration...
  24. ncbi request reprint Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction
    Wilfried Dinh
    Helios Clinics Wuppertal, Department of Cardiology, Wuppertal, Germany
    Int Heart J 50:421-31. 2009
    ..Elevation of TIMP-1 may be a surrogate marker for increased ECM-turnover. The prognostic relevance needs to be proved in long-term studies...